Are you grappling with the rapid evolution of the influenza A virus or the challenge of developing broadly protective therapies? Creative Biolabs' IAV NA Specific Neutra™ Antibody Products empower your research with high-precision, validated neutralizing antibodies, engineered through advanced protein engineering and epitope-focused design, to accelerate the development of next-generation antivirals and universal vaccines.
Influenza A virus Neuraminidase (IAV NA) is a critical surface glycoprotein and a primary target for antiviral intervention. As an essential enzyme for viral replication and spread, NA facilitates the release of nascent virions from infected host cells by cleaving sialic acid residues. Its functional integrity is paramount for successful viral propagation. IAV NA exists as a homotetramer on the viral envelope. It is classified into subtypes (N1-N11) based on antigenic variation, co-circulating with Hemagglutinin (HA) subtypes. This antigenic drift and shift necessitate continuous monitoring and updated countermeasures.
The IAV NA active site is highly conserved across subtypes, presenting a strategic target for broad-spectrum inhibitors and antibodies. High-resolution structures reveal key functional and antigenic domains. Antibodies targeting conserved epitopes, particularly within the enzymatically active site or adjacent conserved regions, can potently inhibit NA activity and viral egress, offering a barrier to the emergence of escape mutants.
Fig.1 Scheme of IAV.1
Widespread use of NA inhibitors has led to the emergence of resistant strains (e.g., H275Y mutation in N1), diminishing therapeutic efficacy. These mutations can alter viral fitness and pathogenicity. IAV NA also plays a role in modulating host immune responses, including potential effects on cytokine signaling, thereby influencing disease severity.
Neuraminidase (NA) is primarily known for its enzymatic role in cleaving sialic acid to release progeny virions. However, NA also initiates cellular signaling by activating TGF-β through the removal of sialic acids from its latent complex. This activation triggers the Smad2/3 signaling pathway, which promotes epithelial-mesenchymal transition and increases susceptibility to secondary bacterial infections. Additionally, NA-mediated sialic acid depletion can modulate PI3K/Akt and MAPK/ERK pathways, facilitating viral motility through the mucus layer and enhancing late-stage viral budding and apical transport.
IAV is the causative agent of seasonal and pandemic influenza, responsible for significant annual morbidity and mortality worldwide. Complications include pneumonia, acute respiratory distress syndrome (ARDS), and exacerbation of underlying conditions, highlighting the urgent need for effective therapeutics.
Fig.2 Schematic depiction illustrating the function of the M2 protein within the influenza A virus (IAV) life cycle.2
Anti-IAV NA monoclonal antibodies (mAbs) offer a direct therapeutic avenue, especially against NA inhibitor-resistant strains. Administered intravenously, these mAbs can reduce viral load, mitigate lung pathology, and improve clinical outcomes in severe infection models. Their mechanism—inhibiting viral release—complements standard-of-care and can be effective even when initiated post-infection, providing a crucial tool for hospitalized patient management.
Prophylactic administration of broadly neutralizing anti-NA antibodies can provide immediate, short-term protection for vulnerable individuals, such as the immunocompromised or elderly, during outbreaks or prior to vaccine efficacy. This passive immunization strategy bridges protection gaps, particularly when circulating strains mismatch vaccine formulations or when vaccine response is suboptimal.
Quantifying NA-inhibiting (NI) antibody titers is a vital complement to traditional hemagglutination inhibition (HI) assays for evaluating vaccine immunogenicity. Anti-NA antibodies serve as critical reagents to standardize these NI assays, helping to establish correlates of protection and driving the development of vaccines designed to elicit stronger, broader NA-specific responses for more universal coverage.
Creative Biolabs delivers a premium portfolio of recombinant anti-IAV NA antibodies, engineered for exceptional performance in demanding research and development:
Creative Biolabs is your trusted partner in virology and immunology research. We combine deep scientific knowledge of targets like IAV NA with cutting-edge production platforms to provide researchers with reliable, high-performance tools. Our antibodies are engineered to deliver the specificity, affinity, and consistency required to translate discoveries into potential therapies. Contact our scientific team today to discuss how our IAV NA Specific Neutra™ Antibody Products can be tailored to your specific project needs.
References
Anti-IAV NA Neutralizing Antibody (V3S-0522-YC6813) (CAT#: V3S-0522-YC6813)
Target: IAV NA
Host Species: Human
Target Species: Influenza A virus (IAV),
Application: Inhib,ELISA,RIA,
Anti-IAV NA Neutralizing Antibody (V3S-0522-YC6814) (CAT#: V3S-0522-YC6814)
Target: IAV NA
Host Species: Human
Target Species: Influenza A virus (IAV),
Application: Inhib,ELISA,RIA,
Anti-IAV NA Neutralizing Antibody (V3S-0522-YC6815) (CAT#: V3S-0522-YC6815)
Target: IAV NA
Host Species: Human
Target Species: Influenza A virus (IAV),
Application: Inhib,ELISA,RIA,
Anti-IAV NA Neutralizing Antibody (V3S-0522-YC6816) (CAT#: V3S-0522-YC6816)
Target: IAV NA
Host Species: Human
Target Species: Influenza A virus (IAV),
Application: Inhib,ELISA,RIA,
Recombinant Anti-IAV NA Antibody (V3S-0522-YC7463) (CAT#: V3S-0522-YC7463)
Target: IAV NA
Host Species: Mouse
Target Species: Influenza A virus (IAV),
Application: ELISA,FuncS,
Anti-IAV NA (C422, T435) Neutralizing Antibody (V3S-1022-YC3936) (CAT#: V3S-1022-YC3936)
Target: IAV NA
Host Species: Mouse
Target Species: A/Chicken/Pennsylvania/1370/1983 (H5N2),
Application: Neut,
Anti-IAV NA Neutralizing Antibody (V3S-1022-YC4600) (CAT#: V3S-1022-YC4600)
Target: IAV NA
Host Species: Mouse
Target Species: Influenza A virus (A/tern/Australia/G70C/1975 (H11N9)),
Application: Block,ELISA,
IAV NA (K432) Specific Neutra™ Antibody (V3S-0923-XY40), Human IgG (CAT#: V3S-0923-XY40)
Target: IAV NA
Host Species: Human
Target Species: IAV (N1, N9),
Application: ELISA,SPR,Neut,Inhib,
IAV NA Specific Recomb™ Antibody (V3S-1023-FY80), Mouse IgG (CAT#: V3S-1023-FY80)
Target: IAV NA
Host Species: Mouse
Target Species: Influenzavirus A Subtype H1N1 (H1N1),
Application: ELISA,